(Total Views: 342)
Posted On: 08/20/2020 8:55:49 AM
Post# of 36568
GNBT not the only one having problems with headlines. CYDY just today:
"After Several Months of Providing Requested Information About Manufacturing and Safety of Leronlimab, U.K.’s MHRA Accepts CytoDyn’s Request to Enroll in its Current Phase 3 Trial for COVID-19 Patients with Severe-to-Critical Symptoms"
Nothing in the part before the first comma was important and it would give new investors concern about a delay, when in actuality it is a normal process in the UK.
"After Several Months of Providing Requested Information About Manufacturing and Safety of Leronlimab, U.K.’s MHRA Accepts CytoDyn’s Request to Enroll in its Current Phase 3 Trial for COVID-19 Patients with Severe-to-Critical Symptoms"
Nothing in the part before the first comma was important and it would give new investors concern about a delay, when in actuality it is a normal process in the UK.
(1)
(0)
